|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-33.00/-0.13
|
企业价值
19.54M
|
资产负债 |
每股账面净值
0.39
|
现金流量 |
现金流量率
--
|
损益表 |
收益
5.00K
|
每股收益
0.18
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 04:26 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. |